Pharma Digital Collaboration - (angol nyelven)
Az egészségügyi rendszerek fenntartható fejlesztése és a globális kihívások kezelése szoros együttműködést kíván a gyógyszeripar, kormányzat, civil szféra és nemzetközi szervezetek között. Ebben kulcsszerepük van a digitális, adatvezérelt döntéstámogató rendszereknek, amelyek segítik a klinikai döntéshozatalt, a személyre szabott terápiákat és az ellátás minőségének javítását. Az ilyen többoldalú, intézményesített együttműködések hozzájárulhatnak a kollektív tudás és erőforrások mozgósításához, az ellátás hozzáférhetőségének bővítéséhez és a globális egészségbiztonság megerősítéséhez.
From Drug Development to Digital Health: Building Integrated Ecosystems How pharma companies can move beyond traditional R&D and embrace digital health as part of their therapeutic offering. Partnerships with digital health startups, health systems, and regulators.
Clinical Decision Support Systems (CDSS): Enabling Data-Driven Therapies The role of CDSS in guiding clinical decision-making, personalizing treatments, and improving patient outcomes. How pharma can contribute by integrating trial data, real-world evidence, and digital biomarkers into these systems.
Data Interoperability and Trust: Breaking Down Silos in Healthcare Creating frameworks for data sharing between pharma, health systems, and public health institutions. Addressing challenges of privacy, cybersecurity, and patient trust.
Scaling Access in Underserved Regions: Pharma’s Role in Global Health Equity How digital platforms and decision support tools can make treatments more accessible. Models for cross-sector collaboration to strengthen healthcare resilience in vulnerable regions.
Value-Based Care and Digital Therapeutics: New Business Models for Pharma Integrating digital health solutions into reimbursement and value-based frameworks. Pharma’s role in shaping sustainable financial models for digital-enabled therapies.
Regulatory and Policy Innovation: Enabling Safe but Rapid Adoption How regulators, pharma, and international organizations can co-create adaptive frameworks. Lessons learned from COVID-19 in fast-tracking digital health adoption.
Strengthening Global Health Security through Multilateral Collaboration Joint efforts between pharma, WHO, NGOs, and governments to prepare for future health crises. The role of digital surveillance, early warning systems, and shared therapeutic data.
Human-Centered Innovation: Designing Digital Health for Clinicians and Patients Ensuring usability and clinical relevance of decision support tools. Co-creation approaches with patients, physicians, and pharma stakeholders.
Sean. R. Smith (MSD)
Enhancing Partnerships Through Digital Activities to Support Improvement of Health Outcomes
Nationwide epidemiological studies using real-world evidence (RWE) provide an accurate picture of disease prevalence, treatment outcomes and the evolution of population health. Applications include the design of health programmes, development of targeted screening and prevention initiatives, strategic resource allocation within the healthcare system and patient-pathway optimisation to achieve better therapeutic outcomes. For example, MSD was the first to develop comprehensive survival quality indicators for some of the most common cancer types, broken down by sex, age group, and year of diagnosis. By producing important data, the quality of Hungary’s oncology care became internationally comparable for the first time. These achievements couldn’t have happened without valuable partnerships with the largest medical associations, hospitals and university research groups.
In addition, by partnering with Semmelweis University, the largest medical university in the region, companies are partnering to identify and develop programmes with a shared goal to improve patient outcomes. To name a few, these include a novel data analysis project based on university databases the improvement of clinical trials implementation, and patient pathway programming. As patient journeys are becoming more complex, with increasing workloads on hospitals, an ageing population and a rising number of newly diagnosed cancer cases, diagnostic and therapeutic options are evolving. However, monitoring performance and implementing best practices are challenging, leading to delays, fragmented patient journeys and wasted time. MSD has over 8 years of experience in patient journey optimization, working with over 50 European hospitals and has proven to reduce time from diagnosis to treatment and waiting times. The Pathway Optimalization Programme is a non-promotional collaboration that provides expertise and support to hospital-based healthcare professionals to run patient journeys more effectively. The programme uses a structured approach that includes setting common goals, identifying bottlenecks, collecting and analyzing data, and developing and implementing action plans. MSD acts as a facilitator to the hospital teams, supporting the dynamics and practical framework of the project, while leaving the decisions and solutions in the hands of the hospitals. Currently, there are more than 4 Hungarian hospitals involved in the programme, including some of the largest hospitals in the country.
MSD Pharma Hungary Kft. 1095 Budapest, Lechner Ödön fasor 10/B, +36-1-888-5300,
hungary_msd@msd.com, date of closing: 11/11/2025. HU-NON-01938
Sinkovits Balázs (AstraZeneca)
Developed societies are all struggling with the same problem: the aging population is placing an increasing burden on countries – both from disease burden, and consequently, from a financial perspective. The significant increase of patients' needs can be handled efficiently only with the co-operation of all players in the health ecosystem: health care providers, policy shapers, researchers, drug developers, payers etc. Public and private entities need to work together to be and remain competitive in the Hungarian and also in the European landscape.How? Digitalized and well organized healthcare benefitting from rapidly-advancing medicines and technologies is the only way to secure active workforce and low societal costs. We all need to work more with prevention, identify diseases as early as possible and treat them effectively to avoid huge labor and resource demanding hospital and social care costs. Although technology is often available, what makes the bigger challenge is to identify and reach patients as early as possible, and also, to finance the system.Hungary's unique data wealth, particularly the information available in the EESZT, offers enormous opportunities for primary and secondary research. Data-driven healthcare decision-making is gaining an increasingly important role, contributing, for example, to preventive medicine, more successful patient journey management, the prevention of public health problems and faster diagnosis.AstraZeneca, as a prominent domestic representative of national public health initiatives, participates in public-private partnerships and supports university research. To mention some great concrete examples, we are working with the Faculty of Public Health at Semmelweis University to process a wide range of healthcare data in the field of respiratory diseases (COPD,severe asthma) using artificial intelligence and data science tools, aiming to achieve more successful patient journey management and more effectively prevent and treat a disease that is a public health problem. Also, together with the University of Pécs, we are working to better identify the number of people with recently diagnosed and end-stage renal disease (ESRD) inHungary, which is now a public health problem to improve patient care.The next step is organizing these initiations in a more structured way, scaling them up with the collaboration of all stakeholders. We strongly believe that putting together the knowledge of all stakeholders can only lead to success.
HU-11523 Lezárás dátuma: 2025. 11. 13.